Steridoc

Mehrfache , sterile Konnektion geschlossener Systeme

The Project

Novel biological drugs offer fantastic possibilities, especially in cancer therapy, and are therefore the focus of pharmaceutical manufacturers and the manufacturers of the necessary technology. One of the most important show stoppers is that production has to take place in extremely expensive and complex clean rooms to ensure sterility, which results in extremely high costs and therefore these new healing opportunities can only be offered to very few patients. A still unsolved problem in automatic sterile production is the connection of sterile, closed containers, which makes clean rooms essential. Our product makes it possible to safely create the necessary connections outside of clean rooms and thus reduce costs to such an extent that a significantly larger number of patients can benefit. The target group is manufacturers of production equipment and systems in the field of cell culture and medical technology.

The Team

Location: Fraunhofer IPA

Members: Michael Pfeifer (Wiss. Mitarbeiter), Richard Rösch (Wiss. Mitarbeiter), Markus Schandar (Wiss. Mitarbeiter), Andreas Traube (Abteilungsleiter)

AHEAD Infos   **Batch:** 13 & 2023   **Phase:** 1   **Track:** Licensing

The Business Model

Unique Selling Proposition: Our technology gives the customer a decisive market advantage. Its products have significantly broader application possibilities

Unfair Advantage: Patents (pending) for 2 sterile connection technologies. Know-How through existing prototype and first validation tests

Revenue Model: Licensing a technology that can be used variably

Venture Readiness Level

VRL	Ideation	Incubation	Traction	Growth

Technology Readiness Level

TRL	1	2	3	4	5	6	7	8	9

The Side Facts

Customer Focus: B2B

Searching For: Interview partner (customer and end-user), customer with licensing interest

Industry Tags: (Health care), pharma, life science

Technology Tags: Lab equipment, medical devices, personalized treatment